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Is the Answer Now Clear?*
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After decades of study, the appropriate strategy for man-
aging asymptomatic patients with severe mitral regurgita-
tion (MR) remains controversial. Because no randomized,
controlled trials (RCTs) have been performed, current
“practice guidelines” are based on inferences drawn from
comparison of observational cohorts. Generally perceived
consistency among these studies has led to a relatively ﬁrm
consensus that asymptomatic patients should undergo
mitral valve surgery when they manifest any one of several
“high risk descriptors,” identiﬁed from the observational
cohorts (1–3), unless symptoms develop ﬁrst. Moreover, asSee page 2398more and more data have accumulated and the risks of
surgery have progressively diminished, it has been sug-
gested that severe MR, itself, should be an indication for
surgery and that “watchful waiting” (i.e., close follow-up to
detect the earliest occurrence of symptoms or high risk
descriptors) should be abandoned (4). A caveat associated
with the latter recommendation is that surgery is appro-
priate only if mitral valve repair (MVr) is highly likely to be
used rather than mitral valve replacement (MVR) (2). This
caveat is based on the increasingly more strongly held
“article of faith” that, when surgery is needed for MR, MVr
outperforms and is preferable to MVR (5) because of lower
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the contents of this paper to disclose.of long-term anticoagulation, superior residual left ven-
tricular function (due to preservation of valve and sub-
valvular structure and function, even in comparison with
valve replacement performed with chordal preservation),
and so on, despite apparently less durability of MVr than
of MVR. Many published studies support the superiority
of MVr to MVR, but, as for surgery versus watchful
waiting, such support is based on inferences from matched
observational cohorts, not from RCTs. RCTs never have
been performed among patients with degenerative MR
(i.e., MR due to leaﬂet abnormalities, as in mitral valve
prolapse or ﬂail leaﬂet), although very recently the ﬁrst
landmark RCT was performed in patients with functional
MR (i.e., MR due to myocardial disease) (6).
Although their study is a RCT, Kang et al. (7) in this
issue of the Journal have added importantly to the
data informing selection of early surgery versus watchful
waiting by creating a relatively large and recent series and
by performing propensity matching to attempt to simu-
late the strengths of the RCT. Their study included
“610 consecutive patients” who were asymptomatic and
lacked high-risk descriptors or clinically apparent coro-
nary artery disease and who underwent surgery between
1996 and 2009 at 2 large medical centers in South Korea.
Although presented as “prospective”, this study is similar
to others of this genre in that patients actually were part
of ongoing registries established at the 2 centers for
other purposes; patients were identiﬁed as having under-
gone surgery retrospectively and analyzed post hoc. This
approach must be contrasted with that of Rosenhek et al.
(8), who designed a prospective study speciﬁcally to assess
the watchful waiting strategy and performed serial assess-
ments in all patients for this purpose. The Rosenhek et al.
(8) design has the advantage of precision and lower like-
lihood of unintentional selection bias, but it too was a RCT
and used historical controls, potentially misleading, to
conclude that watchful waiting is not inferior to early
surgery.
The Kang et al. (7) design inherently involves potential
unintentional selection biases that preclude unambiguous
interpretation of the results: patients who undergo repair
tend to be younger, less sick, less affected by comorbid-
ities, and, perhaps most importantly in this particular
study, less technically complex than those who undergo
replacement. Moreover, in the study of Kang et al.(7), the
second center was added after the ﬁrst center already had
reported results of an analysis of its registry, speciﬁcally to
add power for a more deﬁnitive conclusion. The details of
the construction of the second registry are not provided.
Nonetheless, although suboptimal, such studies often
produce useful and thought-provoking data that, although
technically hypothesis generating, are used clinically as
if they were hypothesis testing. The reason for this is
that, unfortunately, the optimal RCT study design is
very difﬁcult to mount (e.g., large numbers needed for
adequate power are difﬁcult to recruit, biases of physicians
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poise) and, not surprisingly, has never been performed
to assess optimal strategy for asymptomatic degenerative
MR.
Kang et al. (7) found signiﬁcantly fewer clinical outcome
events among the group undergoing early surgery than
among those who underwent watchful waiting. The results
clearly support the strategy of early surgery based on the
presence of severe MR alone. The authors’ methodology is
praiseworthy in that patients were censored when they
reached a high-risk descriptor that would have triggered
surgery if guidelines had been observed, thus avoiding in-
clusion of events that, in theory, might have been pre-
ventable. The 610-patient study is relatively large for a valve
disease outcome study, but quite small when compared with
the thousands commonly included in, for example, heart
failure studies (9). More importantly, however, only 92
outcome events were recorded among these patients, a
relatively small number that minimizes conﬁdence in the
quantitative precision of the relative risk calculations.
Moreover, the authors concluded that patients assigned to
1 strategy or the other were not rigorously comparable,
minimizing the value of a statistical assessment. Therefore,
they undertook a meticulous propensity-matching strategy
to create groups better matched for comparisons. The
propensity-matched population included two-thirds of
the original cohort, or 414 patients, which produced only
61 outcome events, adding greater uncertainty to in-
terpretations of results. Unfortunately, even among the
propensity-matched patients, unintentional selection bias
seems likely: in the early surgery group, 94% underwent
valve repair, putatively the solution providing the better
outcomes. In the “conventional treatment” group, signiﬁ-
cantly fewer of those who underwent surgery had repairs
(82%, p < 0.001). In a retrospective review of data from a
registry designed for a different purpose, it is not surpris-
ing that we have no information about the reason for
nonselection of repair in the “conventional treatment”
group, but it seems likely that factors that mitigated against
performance of repair led to selection of “conventional”
treatment rather than early surgery, in the ﬁrst place,
potentially minimizing the validity of any statistical
comparison.
Although other issues raise concern about interpretation
of post-hoc analysis of these registry data, 1 issue, the use
of drugs, may be of particular concern. Approximately
one-third of the study group received cardioactive drug
therapy. The reason for this therapy is unclear. The authors
have implied that all therapy was for hypertension, alone,
which was said to be present in approximately one-third
of the cohort. The retrospective nature of the data extrac-
tion precludes rigorous conﬁrmation of this inference or
determination of the reasons for selection of speciﬁc
drugs. Certainly, it seems intuitively reasonable to treat
for hypertension in patients with valve disease (although,
in the absence of any evidence, clinicians often usevasodilators in nonhypertensive patients with degenera-
tive MR), but the selection of drugs is another issue.
Both experimental and (the very few available) clinical data
provide no evidence of the beneﬁt and, perhaps, even
detriment, when angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers are used, and recent
experimental data have demonstrated a higher mortality
when severe MR is treated with beta-blockade than with
nothing (10). Kang et al. (7) provide no information about
the relationship of drug use to speciﬁc outcomes, good or
bad. Here, again, a RCT design would have minimized
concern about this potential confounder.
The data of Kang et al. (7) are consistent with the current
growing but unproven consensus that early surgery is better
than watchful waiting for severe asymptomatic MR. How-
ever, in my view, they provide a better argument for the
urgent need for a well-organized, appropriately powered
RCT to assess the best strategy for such patients. Although
such a study never has been mounted, the recent RCT
among patients with functional MR (6) indicates that
this critically important step may be feasible. Indeed, the
functional MR study strengthens the argument for an
RCT for degenerative MR. Until the performance of the
study, it was strongly believed that, for functional MR as
for degenerative MR, repair is the only appropriate choice.
The randomized trial revealed no apparent difference in
survival or in objective functional/geometric outcomes at
12 months after surgery, although the repair group more
frequently manifested recurrent MR. Like all trials, this
RCT had notable deﬁciencies, but its outcome profoundly
altered strongly held conclusions developed solely on a
base of observational data. Although its strengths are
several, the ambiguities of the study of Kang et al. (7)
argue most heavily in favor of a serious effort toward
RCTs to deﬁne appropriate management of asymptomatic
degenerative MR.
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